Credit Hours: CME 1.00

Target Audience:

Gynecologists and women's health practitioners who care for patients during their reproductive years.

Educational Objectives:

Upon completion of this activity, participants should be able to: Upon completion of this activity, participants should be able to:

Recognize the difference between preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD)
Discuss potential indications for PGS.
Discuss risks and benefits associated with PGS

Contact: For questions or technical difficulties, please contact us at infertility@magee.edu

Suggested Additional Reading:

ACOG Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstet Gynecol. 2016;127(5):e123-137.

Ethics Committee of American Society for Reproductive M. Use of preimplantation genetic diagnosis for serious adult onset conditions: a committee opinion. Fertility and sterility. 2013;100(1):54-57.

Scott RT, Jr., Upham KM, Forman EJ, et al. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery rates: a randomized controlled trial. Fertility and sterility. 2013;100(3):697-703.

Authors:

Marie Menke, MD, MPH — Assistant Professor, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, UPMC
Dr. Menke receives grant support from NIH.

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.